EMA Reviews Depression, Anxiety Drug Over Adverse Effects

1 source1 article First seen 2 days ago Updated 2 days ago United States Truth score 38

Save Like Comments Compare coverage

Summary

Deanxit (flupentixol-melitracen) is under review after reports of movement disorders and memory and thinking problems, with some symptoms persisting after treatment was stopped. Medscape News Europe

Description from Medscape.

Who is covering this

Medscape Center Factuality: Mostly factual US 2 days ago
EMA Reviews Depression, Anxiety Drug Over Adverse Effects
Deanxit (flupentixol-melitracen) is under review after reports of movement disorders and memory and thinking problems, with some symptoms persisting after treatment was stopped. Medscape News Europe

Comments

Comments need JavaScript.

Truth score

38/100Weakly supported

Independent outlets: 1
Source reliability: 65/100
Sides of the spectrum covering it: 1/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

Centre 100%100%

Left: 0
Centre: 1
Right: 0
Not rated: 0

How lean is counted

Source quality

Average reliability: 65/100 (Mostly factual)
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

In this story

Medscape News Europe

Filter the stories

Sources Ratings and details

EMA Reviews Depression, Anxiety Drug Over Adverse Effects

Summary

Who is covering this

Comments

Summary

Who is covering this

Comments

Related stories

Maternal FMT May Improve Post-Cesarean Infant Microbiome

Sleepmaxxing: Is the Pursuit of Perfect Sleep Backfiring?

Halved Antenatal Steroids Not Tied to Worse Neurodevelopment

Early Treatment May Delay Rheumatoid Arthritis

Why Do Kidney Disease and Heart Failure Go Together?

Virtual Reality Enters Multimodal Pain Care